1
|
Kashefi S, Mohammadi-Yeganeh S, Ghorbani-Bidkorpeh F, Shabani M, Koochaki A, Safarzadeh M, Hoseini MHM. Anti-cancer Effects of a Chitosan Based Nanoformulation Expressing miR-340 on 4T1 Breast Cancer Cells. J Pharm Sci 2024; 113:445-454. [PMID: 37806438 DOI: 10.1016/j.xphs.2023.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2023] [Revised: 10/02/2023] [Accepted: 10/02/2023] [Indexed: 10/10/2023]
Abstract
MicroRNAs (miRNAs) have a crucial role in the regulation of gene expression in tumor development, invasion, and metastasis. Herein, miRNA-340 (miR-340) has been shown to play tumor suppressor activity in breast cancer (BC). However, the clinical applications of miRNAs request the development of safe and effective delivery systems capable of protecting nucleic acids from degradation. In this study, biodegradable chitosan nanoparticles incorporating miR-340 plasmid DNA (pDNA) (miR-340 CNPs) were synthesized and characterized. Then, the anti-tumor effects of miR-340 CNPs were investigated using 4T1 BCE cells. The spherical nanoparticles (NPs) with an appropriate mean diameter of around 266 ± 9.3 nm and zeta potential of +17 ± 1.8 mV were successfully prepared. The NPs showed good stability, high entrapment efficiency and a reasonable release behavior, meanwhile their high resistance against enzymatic degradation was verified. Furthermore, NPs demonstrated appropriate transfection efficiency and could induce apoptosis, so had toxicity in 4T1 BCE cells. Also, CD47 expression on the surface of cancer cells was significantly reduced after treatment with miR-340 CNPs. The results showed that miR-340 CNPs augmented the expression of P-27 in BC cells. Furthermore, miR-340 CNPs caused down-regulation of BRP-39 (breast regression protein-39) increasingly suggested as a prognostic biomarker for neoplastic diseases like BC. In conclusion, our data show that miR-340 CNPs can be considered as a promising new platform for BC gene therapy.
Collapse
Affiliation(s)
- Sarvenaz Kashefi
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Samira Mohammadi-Yeganeh
- Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Fatemeh Ghorbani-Bidkorpeh
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mahdi Shabani
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Ameneh Koochaki
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Mostafa Haji Molla Hoseini
- Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
2
|
Development and evaluation of polyethylenimine polyplexes as non-viral vectors for delivery of plasmid DNA encoding shRNA against STAT3 activity into triple negative breast cancer cells. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.104113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
3
|
Sharma S, Mazumdar S, Italiya KS, Date T, Mahato RI, Mittal A, Chitkara D. Cholesterol and Morpholine Grafted Cationic Amphiphilic Copolymers for miRNA-34a Delivery. Mol Pharm 2018; 15:2391-2402. [PMID: 29747513 DOI: 10.1021/acs.molpharmaceut.8b00228] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
miR-34a is a master tumor suppressor playing a key role in the several signaling mechanisms involved in cancer. However, its delivery to the cancer cells is the bottleneck in its clinical translation. Herein we report cationic amphiphilic copolymers grafted with cholesterol (chol), N, N-dimethyldipropylenetriamine (cation chain) and 4-(2-aminoethyl)morpholine (morph) for miR-34a delivery. The copolymer interacts with miR-34a at low N/P ratios (∼2/1) to form nanoplexes of size ∼108 nm and a zeta potential ∼ +39 mV. In vitro studies in 4T1 and MCF-7 cells indicated efficient transfection efficiency. The intracellular colocalization suggested that the copolymer effectively transported the FAM labeled siRNA into the cytoplasm within 2 h and escaped from the endo-/lysosomal environment. The developed miR-34a nanoplexes inhibited the breast cancer cell growth as confirmed by MTT assay wherein 28% and 34% cancer cell viability was observed in 4T1 and MCF-7 cells, respectively. Further, miR-34a nanoplexes possess immense potential to induce apoptosis in both cell lines.
Collapse
Affiliation(s)
- Saurabh Sharma
- Department of Pharmacy , Birla Institute of Technology and Science-Pilani (BITS) , Pilani Campus, Vidya Vihar , Pilani - 333031 , Rajasthan , India
| | - Samrat Mazumdar
- Department of Pharmacy , Birla Institute of Technology and Science-Pilani (BITS) , Pilani Campus, Vidya Vihar , Pilani - 333031 , Rajasthan , India
| | - Kishan S Italiya
- Department of Pharmacy , Birla Institute of Technology and Science-Pilani (BITS) , Pilani Campus, Vidya Vihar , Pilani - 333031 , Rajasthan , India
| | - Tushar Date
- Department of Pharmacy , Birla Institute of Technology and Science-Pilani (BITS) , Pilani Campus, Vidya Vihar , Pilani - 333031 , Rajasthan , India
| | - Ram I Mahato
- Department of Pharmaceutical Sciences , College of Pharmacy, University of Nebraska Medical Center , 986125 Nebraska Medical Center , Omaha , Nebraska 68198-6125 , United States
| | - Anupama Mittal
- Department of Pharmacy , Birla Institute of Technology and Science-Pilani (BITS) , Pilani Campus, Vidya Vihar , Pilani - 333031 , Rajasthan , India
| | - Deepak Chitkara
- Department of Pharmacy , Birla Institute of Technology and Science-Pilani (BITS) , Pilani Campus, Vidya Vihar , Pilani - 333031 , Rajasthan , India
| |
Collapse
|
4
|
Salva E, Turan SÖ, Akbuğa J. Inhibition of Glomerular Mesangial Cell Proliferation by siPDGF-B- and siPDGFR-β-Containing Chitosan Nanoplexes. AAPS PharmSciTech 2017; 18:1031-1042. [PMID: 27975193 DOI: 10.1208/s12249-016-0687-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 12/05/2016] [Indexed: 01/23/2023] Open
Abstract
Mesangioproliferative glomerulonephritis is a disease that has a high incidence in humans. In this disease, the proliferation of glomerular mesangial cells and the production of extracellular matrix are important. In recent years, the RNAi technology has been widely used in the treatment of various diseases due to its capability to inhibit the gene expression with high specificity and targeting. The objective of this study was to decrease mesangial cell proliferation by knocking down PDGF-B and its receptor, PDGFR-β. To be able to use small interfering RNAs (siRNAs) in the treatment of this disease successfully, it is necessary to develop appropriate delivery systems. Chitosan, which is a biopolymer, is used as a siRNA delivery system in kidney drug targeting. In order to deliver siRNA molecules targeted at PDGF-B and PDGFR-β, chitosan/siRNA nanoplexes were prepared. The in vitro characterization, transfection studies, and knockdown efficiencies were studied in immortalized and primary rat mesangial cells. In addition, the effects of chitosan nanoplexes on mesangial cell proliferation and migration were investigated. After in vitro transfection, the PDGF-B and PDGFR-β gene silencing efficiencies of PDGF-B and PDGFR-β targeting siRNA-containing chitosan nanoplexes were 74 and 71% in immortalized rat mesangial cells and 66 and 62% in primary rat mesangial cells, respectively. siPDGF-B- and siPDGFR-β-containing nanoplexes indicated a significant decrease in mesangial cell migration and proliferation. These results suggested that mesangial cell proliferation may be inhibited by silencing of the PDGF-B signaling pathway. Gene silencing approaches with chitosan-based gene delivery systems have promise for the efficient treatment of renal disease.
Collapse
|
5
|
Kotmakçı M, Çetintaş VB, Kantarcı AG. Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells. Int J Pharm 2017; 525:101-111. [PMID: 28428090 DOI: 10.1016/j.ijpharm.2017.04.034] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Revised: 04/14/2017] [Accepted: 04/15/2017] [Indexed: 11/25/2022]
Abstract
Developments in the field of molecular oncology have revealed that resistance to chemotherapeutics is acqured through several mechanisms including overexpression of common oncogenic proteins. Signal Transducer and Activator of Transcription 3 (STAT3) is one of these oncogenes that is overexpressed in many cancer types. RNA interference (RNAi) is proven powerful tool for downregulating STAT3, allowing re-sensitization of resistant cancer cells. However, delivery of RNA interference-mediating molecules for STAT3 downregulation in lung cancer cells is limited to a small number of studies most of which employ commercially available transfection kits. The aim of this study was to develop and evaluate cationic solid lipid nanoparticles for delivery of RNAi-mediating plasmid DNA in order to down regulate STAT3 in cisplatin resistant lung cancer cells. We focused on obtaining cSLN:plasmid DNA complexes with size below or equal to 100nm, and a positive zeta potential. Two successful candidate cSLN:plasmid DNA complexes (K2 and K3) were selected for in vitro tests and cell culture studies. These formulations have particle sizes of 98 and 93nm, and zeta potential values of 10.5 and 8.9mV, respectively. Plasmid DNA in these complexes was protected against DNaseI and serum-mediated degradation. Substantial part of DNA retained its supercoiled and circular conformation. TEM images showed nearly spherical complex structure. Both formulations reduced STAT3 expression by approx. 5-fold in cisplatin resistant Calu1 cell line and increased the sensitivity of cells to cisplatin.
Collapse
Affiliation(s)
- Mustafa Kotmakçı
- Department of Pharmaceutical Biotechnology, Ege University Faculty of Pharmacy, 35100 Bornova, Izmir, Turkey.
| | - Vildan Bozok Çetintaş
- Department of Medical Biology, Ege University Faculty of Medicine, 35100 Bornova, Izmir, Turkey
| | - A Gülten Kantarcı
- Department of Pharmaceutical Biotechnology, Ege University Faculty of Pharmacy, 35100 Bornova, Izmir, Turkey
| |
Collapse
|
6
|
Kaban K, Salva E, Akbuga J. The effects of chitosan/miR-200c nanoplexes on different stages of cancers in breast cancer cell lines. Eur J Pharm Sci 2016; 95:103-110. [DOI: 10.1016/j.ejps.2016.05.030] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 05/27/2016] [Accepted: 05/30/2016] [Indexed: 01/31/2023]
|
7
|
Núñez C, Capelo JL, Igrejas G, Alfonso A, Botana LM, Lodeiro C. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials 2016; 97:34-50. [PMID: 27162073 DOI: 10.1016/j.biomaterials.2016.04.027] [Citation(s) in RCA: 80] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2015] [Revised: 04/05/2016] [Accepted: 04/20/2016] [Indexed: 12/21/2022]
Abstract
Breast cancer (BC) is generally classified based on the receptors overexpressed on the cell nucleus, which include hormone receptors such as progesterone (PR) and estrogen (ER), and HER2. Triple-negative breast cancer (TNBC) is a type of cancer that lacks any of these three types of receptor proteins (ER/PR/HER2). Tumor cells exhibit drug resistant phenotypes that decrease the efficacy of chemotherapeutic treatments. Generally, drug resistance has a genetic basis that is caused by an abnormal gene expression, nevertheless, there are several types of drug resistance: efflux pumps reducing the cellular concentration of the drug, alterations in membrane lipids that reduce cellular uptake, increased or altered drug targets, metabolic alteration of the drug, inhibition of apoptosis, repair of the damaged DNA, and alteration of the cell cycle checkpoints. The use of "combination therapy" is recognized as an efficient solution to treat human diseases, in particular, breast cancer. In this review, we give examples of different nanocarriers used to co-deliver multiple therapeutics (chemotherapeutic agent and nucleic acid) to drug-resistant tumor cells, and lastly, we give our recommendations for the future directions for the co-delivery treatments.
Collapse
Affiliation(s)
- Cristina Núñez
- Pharmacology Deparment, Faculty of Veterinary, University of Santiago de Compostela, 27002, Lugo, Spain; C4O Group, Research Unit UCIBIO-REQUIMTE, 2829-516, Caparica, Portugal.
| | - José Luis Capelo
- BIOSCOPE Group, UCIBIO-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516, Caparica, Portugal; ProteoMass Scientific Society, Madan Parque, Rua dos Inventores, 2825-182, Caparica, Portugal
| | - Gilberto Igrejas
- C4O Group, Research Unit UCIBIO-REQUIMTE, 2829-516, Caparica, Portugal; Functional Genomics and Proteomics Unit, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal; Department of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
| | - Amparo Alfonso
- Pharmacology Deparment, Faculty of Veterinary, University of Santiago de Compostela, 27002, Lugo, Spain
| | - Luis M Botana
- Pharmacology Deparment, Faculty of Veterinary, University of Santiago de Compostela, 27002, Lugo, Spain
| | - Carlos Lodeiro
- BIOSCOPE Group, UCIBIO-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516, Caparica, Portugal; ProteoMass Scientific Society, Madan Parque, Rua dos Inventores, 2825-182, Caparica, Portugal.
| |
Collapse
|
8
|
The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF. Int J Pharm 2015; 478:147-154. [DOI: 10.1016/j.ijpharm.2014.10.065] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 10/22/2014] [Accepted: 10/28/2014] [Indexed: 12/31/2022]
|
9
|
Erdem-Çakmak F, Özbaş-Turan S, Şalva E, Akbuğa J. Comparison of VEGF gene silencing efficiencies of chitosan and protamine complexes containing shRNA. Cell Biol Int 2014; 38:1260-70. [DOI: 10.1002/cbin.10317] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Accepted: 05/06/2014] [Indexed: 01/04/2023]
Affiliation(s)
- Fulden Erdem-Çakmak
- Department of Pharmaceutical Biotechnology; Faculty of Pharmacy; Marmara University; Tıbbiye Street 34668 Istanbul Turkey
| | - Suna Özbaş-Turan
- Department of Pharmaceutical Biotechnology; Faculty of Pharmacy; Marmara University; Tıbbiye Street 34668 Istanbul Turkey
| | - Emine Şalva
- Department of Pharmaceutical Biotechnology; Faculty of Pharmacy; Inonu University; Central Campus 44280 Malatya Turkey
| | - Jülide Akbuğa
- Department of Pharmaceutical Biotechnology; Faculty of Pharmacy; Marmara University; Tıbbiye Street 34668 Istanbul Turkey
| |
Collapse
|